Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
480
datasets available to search
ShareScore release 0.7.1
Dataset results
480 results for “Hormone Receptors”
Chemogenomics for NR1 nuclear hormone receptors
<p>Compound information sheets for our chemogenomic library (CGL) for the NR1 family of nuclear hormone receptors.</p> <p>The information sheets contain general information about the substances, the biological activity for the NR main targets and NR off-targets, as well as information about identity and purity.</p>
Figure 4 in Identification of thyroid hormone receptors α and β genes and their expression profiles during metamorphosis in Rana chensinensis*
Figure 4. The levels of rcTRα and rcTRβ mRNA in several (n = 6) tadpoles as assessed by qRT-PCR. Different letters indicate significant differences (P <0.05) between developmental stages.
Figure 2 in Identification of thyroid hormone receptors α and β genes and their expression profiles during metamorphosis in Rana chensinensis*
Figure 2. Phylogenetic relationship of TRs among R. chensinensis and other species. Numbers at the branches are the bootstrap values.
Figure 3 in Identification of thyroid hormone receptors α and β genes and their expression profiles during metamorphosis in Rana chensinensis*
Figure 3. Organ-specific expression of rcTRα and rcTRβ in tadpoles during stages 33–46 by RT-PCR. M: DL2000 DNA marker.
Figure 1 in Identification of thyroid hormone receptors α and β genes and their expression profiles during metamorphosis in Rana chensinensis*
Figure 1. Alignment of TR polypeptide sequences in a few species of Rana. The A/B, DBD, D, and LBD domains are separated by arrows. Two conserved zinc fingers are boxed. Asterisks indicate conserved amino acid and hyphens represent spaces inserted to maximized similarity.
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
ClinicalTrials.gov study NCT01160211. IPD Sharing: YES. Countries: 29. Publications: 2.
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibito
ClinicalTrials.gov study NCT01610284. IPD Sharing: YES. Countries: 29. Publications: 2.
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
ClinicalTrials.gov study NCT03078751. IPD Sharing: YES. Countries: 1. Publications: 1.
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
ClinicalTrials.gov study NCT02278120. IPD Sharing: YES. Countries: 30. Publications: 10.
Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial
ClinicalTrials.gov study NCT03783546. IPD Sharing: YES. Countries: 1. Publications: 1.
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov study NCT03096847. IPD Sharing: YES. Countries: 1. Publications: 1.
Hormone receptors AR, ER, PR and growth factor receptor Her-2 expression in oral squamous cell carcinoma: Correlation with overall survival, disease-free survival and 10-year survival in a high-risk population
<p>Oral squamous cell carcinoma (OSCC) comprises most of head and neck neoplasms and is one of the highest-ranking and lethal cancers in Pakistan due to prevailing mouth habits. Growth and hormonal receptors act as prognostic markers and targets for therapy in some cancers, but their application in OSCC is largely unexplored. This study aimed to evaluate the expression of growth and hormonal receptors in OSCC patients and correlate it with 10-year, overall and disease-free survival. To achieve this objective, immunohistochemistry for Her-2, AR, ER and PR was performed on 100 formalin-fixed paraffin-embedded primary OSCC specimens. Receptor expression was correlated with mouth habits and clinicopathological features and patient survival was analyzed using Kaplan-Meier method and Cox regression univariate analysis. We observed that in 100 patients, there were 57 males and 43 females. Immunopositive Her-2 expression was observed in 21% of patients, AR in 13%, ER in 3% and 0% for PR. Patients with betel quid/areca nut mouth habits had significantly absent Her-2 expression (P=0.035). Also, Her-2 negative patients were also negative for AR expression (P=0.002). Her-2 positive patients had poor 10-year survival (P=0.041). A trend of low survival and high recurrence rate was observed in AR positive patients, but this was not significant (P=0.072). No statistically relevant correlations were seen in the case of ER and PR. In conclusion, Her-2 may be a valuable marker for predicting long-term prognosis of OSCC patients.</p>
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
ClinicalTrials.gov study NCT00382070. IPD Sharing: Not stated. Countries: 3. Publications: 3.
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
ClinicalTrials.gov study NCT01385280. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative
ClinicalTrials.gov study NCT04191499. IPD Sharing: YES. Countries: 28. Publications: 2.
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
ClinicalTrials.gov study NCT01797120. IPD Sharing: NO. Countries: 1. Publications: 1.
Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations
ClinicalTrials.gov study NCT02457897. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
ClinicalTrials.gov study NCT02520063. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
ClinicalTrials.gov study NCT01864746. IPD Sharing: Not stated. Countries: 11. Publications: 9.
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
ClinicalTrials.gov study NCT00390455. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.